Our results indicate that in CRC, YYFZBJS inhibited proliferation and induced apoptosis by modulating the CDK1/PI3K/Akt signaling pathway and highlight YYFZBJS as a promising adjuvant in CRC treatment. This evidence concerns the gene AKT1 and colorectal carcinoma.